Annals of the Rheumatic Diseases

publication venue for

POS1208 EQUITY CONSIDERATIONS IN COVID-19 VACCINATION STUDIES OF INDIVIDUALS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES 2022
AB0857 CERTOLIZUMAB PEGOL RELOADING SUCCESSFULLY CONTROLS INFLAMMATORY ARTHRITIS FLARES DURING PREGNANCY – A CASE REPORT 2021
OP0143 IMPACT OF ADALIMUMAB VERSUS NON-BIOLOGIC THERAPY ON DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN ANKYLOSING SPONDYLITIS OVER 24 MONTHS – RESULTS OF THE COMPLETE-AS CANADIAN OBSERVATIONAL STUDY 2021
FRI0258 CUMULATIVE INCIDENCE, SURVIVAL AND PREDICTORS OF PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS SUBSETS: PAH IS NOT INCREASED IN LIMITED VS DIFFUSE PATIENTS BY ADJUSTED COMPETING RISK ANALYSIS 2020
AB0704 EFFECTIVENESS AND SAFETY OF INFLIXIMAB AND GOLIMUMAB IN ANKYLOSING SPONDYLITIS PATIENTS FROM A PROSPECTIVE OBSERVATIONAL REGISTRY 2019
AB1328 MEASUREMENT PROPERTIES OF THE BRIEF PAIN INVENTORY-SHORT FORM (BPI-SF) AND THE REVISED SHORT-FORM MCGILL PAIN QUESTIONNAIRE-VERSION-2 (SF-MPQ-2) IN PAIN-RELATED MUSCULOSKELETAL CONDITIONS: A SYSTEMATIC REVIEW 2019
AB1345 CONTEXTUAL FACTORS IMPACTING OSTEOARTHRITIS MANAGEMENT IN URBAN AND RURAL COMMUNITY-DWELLING SENIORS: AN ANALYSIS BASED ON THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING DISABILITY AND HEALTH 2019
FRI0550 JIA DISEASE ACTIVITY OUTCOMES ACROSS A MULTI-CENTER COHORT: ANALYSIS OF THE PEDIATRIC RHEUMATOLOGY CARE AND OUTCOMES IMPROVEMENT NETWORK (PR-COIN) REGISTRY 2019
SAT0318 PREVALENCE AND PREDICTORS OF DEPRESSION AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN A CANADIAN REAL WORLD OBSERVATIONAL COHORT: RESULTS FROM THE COMPLETE STUDIES 2019
SAT0613 CHANGING TREATMENTS AND OUTCOMES FOR JUVENILE IDIOPATHIC ARTHRITIS: INITIAL FINDINGS FROM A NEW CANADIAN INCEPTION COHORT 2019
THU0163 A DESCRIPTIVE ANALYSIS OF LONGITUDINAL CHANGES IN RELATIVE MARKET SHARE PROPORTIONS OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS: DATA FROM THE OBRI DATABASE 2019
THU0371 PREVALENCE OF WORK DISABILITY AND PREDICTORS OF WORK PRODUCTIVITY AMONG EMPLOYABLE PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN A CANADIAN REAL WORLD OBSERVATIONAL COHORT: INTERIM RESULTS FROM THE COMPLETE STUDIES 2019
AB0935 Canadian adalimumab post-marketing observational epidemiological study assessing the effectiveness of adalimumab vs non-biologic dmards in psoriatic arthritis (COMPLETE-PSA): 12-month effectiveness data 2018
AB0939 Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study 2018
AB1239 The brazilian rheumatology triage: an assessment of the primary healthcare system 2018
FRI0217 Diagnostic ascertainment of axial spondyloarthritis in patients presenting with undiagnosed back pain: what is the impact of mri in rheumatological practice? 2018
FRI0626 Screening for tuberculosis before tnf inhibitor therapy remains suboptimal: a multi-specialty, real world, nationwide experience in the united states 2018
OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab 2018
SAT0290 Canadian adalimumab post-marketing observational epidemiological study assessing the effectiveness of adalimumab vs. non-biologic dmards in ankylosing spondylitis (COMPLETE-AS): 12-month effectiveness data 2018
SAT0565 Adjusting for the intra-articular placebo effect in knee osteoarthritis therapies 2018
FRI0684 Early treatment with methotrexate improves all-cause and cardiovascular survival among an inception cohort of seniors with rheumatoid arthritis 2017
OP0192 Adding ultrasound to the treat-to-target strategy shows no benefit in achievement of remission: results from the biodam cohort 2017
SAT0428 Which criteria for inflammatory back pain in spondyloarthritis are optimal? data from the screening for axial spondyloarthritis in psoriasis, iritis, and colitis study (SASPIC) 2017
SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors 2017
THU0561 Clinical practice guideline for diagnosis and management of catastrophic antiphospholipid syndrome 2017
FRI0159 Persistence with Biologic Monotherapy in Comparison with Combination Therapy with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis; Results from An Ontario Rheumatoid Arthritis Cohort 2016
FRI0187 A Randomized Crossover Comparison of Injection Site Pain with 40 Mg/0.8 Ml and 40 mg/0.4 ml Formulations of Adalimumab in Patients with Rheumatoid Arthritis 2016
FRI0221 Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in A Clinical Setting: 2016
THU0067 Is Treat-To-Target Really Working? A Longitudinal Analysis in Biodam 2016
AB1163 Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab 2015
SAT0338 Does Treatment Improve HAQ or Do Patients Adjust How They Do Things? An Exploration of the HAQ-DI Vs the HAQ-ADI Over Time 2015
SAT0348 The Economic Value of Tofacitinib 5 Mg Bid in the Treatment of Moderate to Severe Rheumatoid Arthritis: A Canadian Analysis 2015
SAT0433 Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease – the Lotuss Study 2015
SAT0507 Growth and Weight Gain in Children with Juvenile Idiopathic Arthritis: Results from the Reacch-Out Cohort 2015
SAT0557 Predictors of Response in Patients with Psoriatic Arthritis Treated with Anti-TNF in a Real-World Setting 2015
AB0221 Does Etanercept Maintain Its Efficacy in the Elderly Population. A Single Center Retrospective Analysis 2014
AB0228 Variability in Patient Characteristics and Outcomes in Rheumatoid Arthritis upon Infliximab Treatment Based on the Size of the Biologic Treatment Registry Site 2014
AB1044 Are There Gender Specific Differences in Patient Reported Outcomes at Initiation of Golimumab Treatment in Rheumatoid Arthritis? 2014
FRI0194 Identifying Patients with Rheumatoid Arthritis in Primary Care Electronic Medical Records 2014
OP0200 Thromboembolism in Rheumatology: Investigation of the Risks of Deep Vein Thrombosis and Pulmonary Embolism in Inflammatory Arthritis, Connective Tissue Diseases, Vasculitis and Myositis: 2014
SAT0035 Impact of Corticosteroid Use on Remission Sustainability and Infection Rates among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on A Real-World Population 2014
SAT0083 Does Specific Joint Involvement in Rheumatoid Arthritis Patients PREDICT Patient Reported Outcomes? Implications for Clinical Practice 2014
SAT0458 How Does Non-Compliance to Prolia ® (DENOSUMAB) Affect the Change in Bone Mineral Density (BMD)? 2014
SAT0576 Creating New Rheumatologists: the Canadian Experience 2014
THU0153 Pregnancy Outcomes in Women Exposed to the Tumor Necrosis Factor Inhibitor, Golimumab 2014
THU0241 Predictors of Acr/Eular Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: an Analysis from the Prospective, Observational Registry, Biotrac 2014
THU0416 Attrition Bias in Rheumatoid Arthritis Randomised Trials with Different Modified Intention-To-Treat Approaches: A Meta-Epidemiological Study: Table 1 2014
THU0498 Increase of CXCR3-CCR4+CCR6+CCR10- Memory T Helper Cells (TH17-LIKE) in Patients with Granulomatosis and Polyangiitis (GPA) 2014
CORRELATION OF INDIVIDUAL HAQ QUESTIONS WITH OUTCOME MEASURES IN RHEUMATOID ARTHRITIS: IMPLICATIONS FOR INSTRUMENT REDUCTION 2013
CORTICOSTEROID USE IN RHEUMATOID ARTHRITIS PATIENTS ON INFLIXIMAB: TREATMENT IMPLICATIONS BASED ON A REAL-WORLD CANADIAN POPULATION 2013
EPIDEMIOLOGY OF RHEUMATOID ARTHRITIS IN A UNIVERSAL PUBLIC HEALTH CARE SYSTEM: RESULTS FROM THE ONTARIO RA ADMINISTRATIVE DATABASE (ORAD). 2013
FRI0410 Rheumatoid arthritis (RA) care: Geographic disparities and impact of primary care physicians on access to rheumatologists 2013
FRI0431 Why the findings of published rheumatoid arthritis multiple treatment comparisons are so different – an overview of recurrent methodological shortcomings 2013
OP0277 Burden of childhood CNS vasculitis: Identifying high risk factors for poor cognitive outcome 2013
SAFETY, EFFECTIVENESS, WORK AND HOUSEHOLD PRODUCTIVITY OF ANTI-TNF ALPHA THERAPY WITH CERTOLIZUMAB PEGOL OBSERVED IN ADULT RHEUMATOID ARTHRITIS PATIENTS IN DAILY PRACTICE IN CANADA: FIRST INTERIM ANALYSIS OF THE NON-INTERVENTIONAL FAST CAN STUDY 2013
SAT0101 Das does not predict increasing treatment in early rheumatoid arthritis (ERA): Results from the catch study: 2013
SHARED DECISION MAKING AT THE FAMILY-HEALTH UNIT: PATIENT'S PERSPECTIVE 2013
VARIABILITY IN THE CLASSIFICATION OF REMISSION AMONG DISEASE ACTIVITY INDICES AND THEIR CORRELATION: AN ANALYSIS FROM A PROSPECTIVE, OBSERVATIONAL REGISTRY 2013
An algorithm for cardiopulmonary testing in systemic sclerosis 2007
Development and testing of decision board tools in to describe treatment options in lupus nephritis 2007
Lupus nephritis treatment: Assessing different preferences between patients and physicians using a decision board instrument in Brazil 2007
Willingness to pay as an instrument to measure preferences in lupus nephritis treatment 2007
Between-group differences in ultrasonographic measures of synovitis and kinetics of response to oral steroids in active RA 2006
Comparative analysis of performance of DAS 28 and new indexes SDAI and CDAI in early arthritis: Are they equally useful for assessment of disease activity and therapeutic decision making? 2006
Efficacy and safety of adalimumab (Humira (R)) in Canadian clinical practice: Results from the canact trial 2006
Physical activity and exercise in kids (peak): The effects of vigorous exercise training on motor function and functional fitness in children with arthritis 2006
Reliability of exercise testing parameters in children with juvenile arthritis 2006
Validation, translation into Brazilian-Portuguese and cultural adaptation of the BASFI and BASDAI 2006
Efficacy and safety of adalimumab (HUMIRA (R)) in Canadian clinical practice. A comparison of the Canadian and the European practice: The canact and the react trial to 2005
Resource utilization and costs of rheumatoid arthritis in Brazil 2005
Enbrel community health outcomes study: Health outcomes from patients with rheumatoid arthritis using etanercept in a community based setting 2004
Examining minimal perceptible clinical improvement criteria in patients treated with hylan G-F 20 for knee ostecarthritis 2004
Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care 2004
Womac 20,50,70 response levels in patients treated with hylan G-F 20 for knee osteoarthritis 2004
Demonstrated safety with daily subcutaneous (SC) injections of Kineret (R) (Anakinra "C recombinant interleukin-1 receptor antagonist) in a standard practice population 2003
Patient function improved as measured by the health assessment questionnaire - Disability index (HAQ-DI), following daily subcutaneous (SC) injections of kineret; (Anakinra-recombinant interleukin-1 receptor antagonist) in a standard practice populatio 2003
Resource utilization in postmenopausal osteoporosis 2003
Twelve-month follow-up results for the etanercept community health outcomes [ECHO] study 2003
Plasma proteome profiling in giant cell arteritis. ard-2024-225868. 2024
2023 ACR/EULAR antiphospholipid syndrome classification criteria. 82:1258-1270. 2023
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. 82:937-944. 2023
AB1591 POLICY DRIVERS FOR MARKET PENETRATION OF ANTI-TNF BIOSIMILARS: MULTI-COUNTRY COMPARISONS. 82:2029-2030. 2023
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. 81:1085-1095. 2022
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. 79:1243-1249. 2020
Response to: ‘Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Joneset al’by Vandergheynstet al. 79:e101-e101. 2020
Correction:Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). 79:e77-e77. 2020
THU0318 PATTERNS OF CLINICAL PRESENTATION IN TAKAYASU’S ARTERITIS. 79:388.1-388. 2020
Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. 79:612-617. 2020
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). 79:453-459. 2020
All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013). 78:802-806. 2019
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. 78:807-816. 2019
Common mental disorders within chronic inflammatory disorders: a primary care database prospective investigation. 78:688-695. 2019
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. 78:399-405. 2019
SAT0631-HPR Chronic Disease and Self-Injection: Ethnographic Investigations into The Patient Experience during Treatment. 75:1291.4-1292. 2016
The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. 75:1092-1098. 2016
The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. 74:1854-1860. 2015
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. 74:1178-1182. 2015
Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. 72:1524-1535. 2013
An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). 72:911-917. 2013
FRI0280 Cd4+cd25highfoxp3+ t regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study. 72:A469.1-A469. 2013
Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. 71:1329-1334. 2012
High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis. 70:690-694. 2011
Are they relevant? A critical evaluation of the international classification of functioning, disability, and health core sets for osteoarthritis from the perspective of patients with knee osteoarthritis in Singapore.. 65:1067-1073. 2006
Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. 64:881-885. 2005
Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. 60:1088-1094. 2001
Lymphocyte and neuronal antigens in neuropsychiatric lupus: presence of an elutable, immunoprecipitable lymphocyte/neuronal 52 kd reactivity.. 53:304-308. 1994
Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus.. 49:249-253. 1990
Management of NSAID induced gastrointestinal disturbance.. 46:640-643. 1987
Sweat gland function in Sjogren's syndrome.. 45:350-351. 1986
Radiological articular involvement in the dominant hand in rheumatoid arthritis.. 39:508-510. 1980

Annals of the Rheumatic Diseases Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)